Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease

G. Vendemiale, E. Altomare, T. Trizio, C. Le Grazie, C. Di Padova, M. T. Salerno, V. Carrieri, O. Albano

Research output: Contribution to journalArticle

Abstract

S-Adenosyl-l-methionine (SAMe) is a physiologic precursor of thiols and sulfurated compounds, which are known to be decreased in patients with liver disease. The effect of its administration on the hepatic glutathione content of liver patients was investigated. Four groups of subjects were selected: a) 9 patients with alcoholic liver disease treated with SAMe (1.2g/day orally for 6 months); b) 7 patients with nonalcoholic liver disease treated as above; c) 8 placebo-treated patients with alcoholic liver disease; and d) 15 normal subjects as a control group. Total and oxidized glutathione were assayed by high-performance liquid chromatography of liver biopsy specimens before and after the treatment period. In all patients pre-treatment hepatic glutathione was significantly decreased as compared with controls. SAMe therapy resulted in a significant increase of hepatic glutathione levels both in patients with alcoholic and in those with non-alcoholic liver diseases as compared with placebo-treated patients. SAMe may therefore exert an important role in reversing hepatic glutathione depletion in patients with liver disease.

Original languageEnglish
Pages (from-to)407-415
Number of pages9
JournalScandinavian Journal of Gastroenterology
Volume24
Issue number4
DOIs
Publication statusPublished - 1989

Fingerprint

Methionine
Glutathione
Liver Diseases
Liver
Alcoholic Liver Diseases
Placebos
Glutathione Disulfide
Sulfhydryl Compounds
Therapeutics
High Pressure Liquid Chromatography
Biopsy
Control Groups

Keywords

  • Alcohol
  • Glutathione
  • Liver disease
  • S-adenosyl-l-methionine

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Vendemiale, G., Altomare, E., Trizio, T., Le Grazie, C., Di Padova, C., Salerno, M. T., ... Albano, O. (1989). Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease. Scandinavian Journal of Gastroenterology, 24(4), 407-415. https://doi.org/10.3109/00365528909093067

Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease. / Vendemiale, G.; Altomare, E.; Trizio, T.; Le Grazie, C.; Di Padova, C.; Salerno, M. T.; Carrieri, V.; Albano, O.

In: Scandinavian Journal of Gastroenterology, Vol. 24, No. 4, 1989, p. 407-415.

Research output: Contribution to journalArticle

Vendemiale, G, Altomare, E, Trizio, T, Le Grazie, C, Di Padova, C, Salerno, MT, Carrieri, V & Albano, O 1989, 'Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease', Scandinavian Journal of Gastroenterology, vol. 24, no. 4, pp. 407-415. https://doi.org/10.3109/00365528909093067
Vendemiale, G. ; Altomare, E. ; Trizio, T. ; Le Grazie, C. ; Di Padova, C. ; Salerno, M. T. ; Carrieri, V. ; Albano, O. / Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease. In: Scandinavian Journal of Gastroenterology. 1989 ; Vol. 24, No. 4. pp. 407-415.
@article{947dcf359f484721b5742215e0bd1c0f,
title = "Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease",
abstract = "S-Adenosyl-l-methionine (SAMe) is a physiologic precursor of thiols and sulfurated compounds, which are known to be decreased in patients with liver disease. The effect of its administration on the hepatic glutathione content of liver patients was investigated. Four groups of subjects were selected: a) 9 patients with alcoholic liver disease treated with SAMe (1.2g/day orally for 6 months); b) 7 patients with nonalcoholic liver disease treated as above; c) 8 placebo-treated patients with alcoholic liver disease; and d) 15 normal subjects as a control group. Total and oxidized glutathione were assayed by high-performance liquid chromatography of liver biopsy specimens before and after the treatment period. In all patients pre-treatment hepatic glutathione was significantly decreased as compared with controls. SAMe therapy resulted in a significant increase of hepatic glutathione levels both in patients with alcoholic and in those with non-alcoholic liver diseases as compared with placebo-treated patients. SAMe may therefore exert an important role in reversing hepatic glutathione depletion in patients with liver disease.",
keywords = "Alcohol, Glutathione, Liver disease, S-adenosyl-l-methionine",
author = "G. Vendemiale and E. Altomare and T. Trizio and {Le Grazie}, C. and {Di Padova}, C. and Salerno, {M. T.} and V. Carrieri and O. Albano",
year = "1989",
doi = "10.3109/00365528909093067",
language = "English",
volume = "24",
pages = "407--415",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease

AU - Vendemiale, G.

AU - Altomare, E.

AU - Trizio, T.

AU - Le Grazie, C.

AU - Di Padova, C.

AU - Salerno, M. T.

AU - Carrieri, V.

AU - Albano, O.

PY - 1989

Y1 - 1989

N2 - S-Adenosyl-l-methionine (SAMe) is a physiologic precursor of thiols and sulfurated compounds, which are known to be decreased in patients with liver disease. The effect of its administration on the hepatic glutathione content of liver patients was investigated. Four groups of subjects were selected: a) 9 patients with alcoholic liver disease treated with SAMe (1.2g/day orally for 6 months); b) 7 patients with nonalcoholic liver disease treated as above; c) 8 placebo-treated patients with alcoholic liver disease; and d) 15 normal subjects as a control group. Total and oxidized glutathione were assayed by high-performance liquid chromatography of liver biopsy specimens before and after the treatment period. In all patients pre-treatment hepatic glutathione was significantly decreased as compared with controls. SAMe therapy resulted in a significant increase of hepatic glutathione levels both in patients with alcoholic and in those with non-alcoholic liver diseases as compared with placebo-treated patients. SAMe may therefore exert an important role in reversing hepatic glutathione depletion in patients with liver disease.

AB - S-Adenosyl-l-methionine (SAMe) is a physiologic precursor of thiols and sulfurated compounds, which are known to be decreased in patients with liver disease. The effect of its administration on the hepatic glutathione content of liver patients was investigated. Four groups of subjects were selected: a) 9 patients with alcoholic liver disease treated with SAMe (1.2g/day orally for 6 months); b) 7 patients with nonalcoholic liver disease treated as above; c) 8 placebo-treated patients with alcoholic liver disease; and d) 15 normal subjects as a control group. Total and oxidized glutathione were assayed by high-performance liquid chromatography of liver biopsy specimens before and after the treatment period. In all patients pre-treatment hepatic glutathione was significantly decreased as compared with controls. SAMe therapy resulted in a significant increase of hepatic glutathione levels both in patients with alcoholic and in those with non-alcoholic liver diseases as compared with placebo-treated patients. SAMe may therefore exert an important role in reversing hepatic glutathione depletion in patients with liver disease.

KW - Alcohol

KW - Glutathione

KW - Liver disease

KW - S-adenosyl-l-methionine

UR - http://www.scopus.com/inward/record.url?scp=0024362244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024362244&partnerID=8YFLogxK

U2 - 10.3109/00365528909093067

DO - 10.3109/00365528909093067

M3 - Article

C2 - 2781235

AN - SCOPUS:0024362244

VL - 24

SP - 407

EP - 415

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 4

ER -